Skip to main content
    K

    Kura Oncology Inc (KURA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.70
    +0.09 (+0.94%)

    Market Cap: $874.48M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    69%(27/39)
    Avg Surprise
    -14.56%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.81
    Range$-0.99 - $-0.70
    10 analysts
    EPS Revisions
    1
    0
    7d
    7
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.90+10.6%
    60d ago$-0.89+9.7%
    30d ago$-0.81+0.1%
    7d ago$-0.81+0.1%
    Current$-0.81
    Revenue Consensus
    $24M
    Range$9M - $29M
    15 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.72
    Range$-1.02 - $-0.52
    10 analysts
    Revenue Consensus
    $26M
    Range$8M - $69M
    15 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.72---
    Sep 26EST
    		-$-0.81---
    Jun 26
    Reported Aug 12
    		$-0.77$-0.89+13.48%Beat-2.7%
    Mar 26
    Reported May 12
    		$-0.83$-0.90+8.35%Beat-25.4%
    Dec 25
    Reported Mar 5
    		$-0.92$-0.49-87.76%Miss-318.2%
    Sep 25
    Reported Nov 4
    		$-0.85$-0.68-25.00%Miss-34.9%
    Jun 25
    Reported Aug 7
    		$-0.75$0.15-600.00%Miss-27.1%
    Mar 25
    Reported May 1
    		$-0.66$-0.60-10.00%Miss-11.9%
    Dec 24
    Reported Feb 26
    		$-0.22N/A+65.49%Beat+60.0%
    Sep 24
    Reported Nov 7
    		$-0.63$-0.61-3.28%Miss-26.0%
    Jun 24
    Reported Aug 8
    		$-0.59$-0.62+4.84%Beat-11.3%
    Mar 24
    Reported May 2
    		$-0.59$-0.54-9.26%Miss-18.0%
    Dec 23
    Reported Feb 27
    		$-0.55$-0.55+0.00%Beat-12.2%
    Sep 23
    Reported Nov 2
    		$-0.50$-0.55+9.09%Beat+5.7%
    Jun 23
    Reported Aug 3
    		$-0.53$-0.56+5.36%Beat-1.9%
    Mar 23
    Reported May 10
    		$-0.50$-0.54+7.41%Beat-2.0%
    Dec 22
    Reported Feb 23
    		$-0.49$-0.57+14.04%Beat+0.0%
    Sep 22
    Reported Nov 3
    		$-0.53$-0.56+5.36%Beat-6.0%
    Jun 22
    Reported Aug 3
    		$-0.52$-0.52+0.00%Beat-2.0%
    Mar 22
    Reported May 4
    		$-0.49$-0.52+5.77%Beat-6.5%
    Dec 21
    Reported Feb 24
    		$-0.49$-0.53+7.55%Beat-8.9%
    Sep 21
    Reported Nov 4
    		$-0.50$-0.54+7.41%Beat-19.0%
    Jun 21
    Reported Aug 5
    		$-0.51$-0.50-2.00%Miss-27.5%
    Mar 21
    Reported May 6
    		$-0.46$-0.42-9.52%Miss-9.5%
    Dec 20
    Reported Feb 24
    		$-0.45$-0.45+0.00%Beat-15.4%
    Sep 20
    Reported Nov 5
    		$-0.42$-0.40-5.00%Miss-16.7%
    Jun 20
    Reported Aug 6
    		$-0.40$-0.43+6.98%Beat-5.3%
    Mar 20
    Reported May 4
    		$-0.42$-0.42+0.00%Beat-13.5%
    Dec 19
    Reported Feb 25
    		$-0.39$-0.41+4.88%Beat+7.1%
    Sep 19
    Reported Nov 5
    		$-0.36$-0.39+7.69%Beat+10.0%
    Jun 19
    Reported Aug 1
    		$-0.38$-0.41+7.32%Beat+15.6%
    Mar 19
    Reported May 7
    		$-0.37$-0.44+15.91%Beat+19.6%
    Dec 18
    Reported Mar 5
    		$-0.42$-0.42+0.00%Beat-13.5%
    Sep 18
    Reported Nov 5
    		$-0.40$-0.43+6.98%Beat-5.3%
    Jun 18
    Reported Aug 6
    		$-0.45$-0.43-4.65%Miss-12.5%
    Mar 18
    Reported May 8
    		$-0.46$-0.35-31.43%Miss-17.9%
    Dec 17
    Reported Mar 12
    		$-0.37$-0.36-2.78%Miss+2.6%
    Sep 17
    Reported Nov 7
    		$-0.38$-0.38+0.00%Beat-
    Jun 17
    Reported Aug 7
    		$-0.40$-0.43+6.98%Beat-
    Mar 17
    Reported May 15
    		$-0.39$-0.42+7.14%Beat-
    Dec 16
    Reported Mar 14
    		$-0.38$-0.40+5.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-2.88EV/EBITDAN/A
    Price/FCF-7.34xFCF Yield-13.62%
    Profitability
    Profit Margin0.00%Operating Margin-349.80%
    ROE-167.70%ROIC-546.35%
    Financial Health
    Debt/Equity0.20xInterest Coverage-224.01x
    Current Ratio4.73xQuick Ratio4.71x
    Trading Statistics
    Beta0.47Avg Volume1.80M
    52-Week High$13.9052-Week Low$7.36

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$10.31
    SMA 20$10.68
    SMA 50$11.32
    SMA 200$9.80
    EMA 10$10.22
    EMA 20$10.60
    EMA 50$10.92
    EMA 200$10.08

    MACD

    Line: -0.43Signal: -0.33Hist: -0.10

    ADX

    ADX: 19.4+DI: 14.1-DI: 27.2

    Aroon & PSAR

    Aroon Up20.0
    Aroon Down96.0
    PSAR$10.61

    Bollinger Bands

    Upper Band$11.82
    Lower Band$9.54
    %B Position2141%(Upper)
    Band Width0.07

    RSI (14-Day)

    Neutral
    30.3

    Momentum Oscillators

    Stoch %K5.4
    Stoch %D9.1
    Williams %R-91.6
    ROC (10d)-8.9%
    Momentum-0.95
    CCI (20d)-165.9
    MFI (14d)49.6

    Volatility Measures

    ATR (14d)$0.48(5.0%)
    StdDev (20d)0.57
    Hist Vol31.4%(Moderate)

    Volume Flow

    VWAP$9.73
    OBV46.1M
    AD Line-29.8M
    CMF (20d)-0.251

    Volume Metrics

    Avg Vol (20d)1.8M
    Vol Ratio0.9x
    VWMA (20d)$10.70

    Pivot Points

    R3$10.08
    R2$9.97
    R1$9.79
    Pivot Point$9.68
    S1$9.50
    S2$9.39
    S3$9.21

    Advanced Oscillators

    TSI-27.92
    Ultimate Osc39.1
    KST-124.30

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$20.87M$18.27M$17.34M$20.75M$15.29M$14.11M$53.88M$0$0$0$1.27M$0
    Cost of Revenue$243,000$262,000$57,000$0$0$0$204,000$0$0$0$214,000$0
    Gross Profit$20.63M$18.00M$17.28M$20.75M$15.29M$14.11M$53.88M$0$0$0$-214,000$0
    Operating Expenses$93.64M$96.82M$103.55M$100.75M$87.95M$78.81M$76.34M$59.88M$56.40M$54.45M$46.76M$42.47M
    R&D$61.89M$65.26M$64.41M$67.91M$62.78M$55.97M$52.27M$41.70M$39.73M$36.27M$32.53M$29.33M
    SG&A$31.75M$31.55M$39.14M$32.84M$25.17M$22.84M$24.07M$18.18M$16.68M$18.18M$14.23M$13.14M
    Operating Income$-73,010,000$-78,815,000$-86,268,000$-79,997,000$-72,666,000$-64,700,000$-22,455,000$-59,884,000$-56,404,000$-54,452,000$-46,762,000$-42,473,000
    Interest Income$5.03M$5.83M$5.69M$6.27M$6.93M$7.88M$5.66M$5.89M$5.97M$5.33M$4.37M$4.28M
    Interest Expense$345,000$336,000$346,000$393,000$391,000$382,000$403,000$412,000$406,000$398,000$394,000$404,000
    Income Before Tax$-68,322,000$-73,325,000$-80,928,000$-74,116,000$-66,122,000$-57,203,000$-17,199,000$-54,404,000$-50,837,000$-49,525,000$-42,786,000$-38,602,000
    Income Tax Expense$5,000$8,000$71,000$0$0$226,000$2.02M$0$0$0$0$0
    Net Income$-68,327,000$-73,333,000$-80,999,000$-74,116,000$-66,122,000$-57,429,000$-19,217,000$-54,404,000$-50,837,000$-49,525,000$-42,786,000$-38,602,000
    EBITDA$-73,271,000$-79,254,000$-87,144,000$-81,616,000$-74,824,000$-66,988,000$-24,996,000$-62,979,000$-59,624,000$-57,366,000$-49,162,000$-45,025,000
    EBIT$-73,010,000$-78,815,000$-86,268,000$-79,997,000$-72,666,000$-64,700,000$-22,455,000$-59,884,000$-56,404,000$-54,452,000$-46,762,000$-42,473,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about KURA

    News

    UBS keeps USD 15.00 target for Kura Oncology stock

    UBS has reiterated a Buy rating and a USD 15.00 price target for Kura Oncology (KURA) stock. This target is 54.64% above the Nasdaq price of USD 9.70 as of October 15...

    ad-hoc-news.de•10/15/26•Somewhat-Bullish

    (KURA) and the Role of Price-Sensitive Allocations

    This article analyzes Kura Oncology Inc. (NASDAQ: KURA), noting weak near and mid-term sentiment despite a positive long-term outlook. AI models have generated three trading strategies for different risk profiles...

    Stock Traders Daily•10/15/26•Somewhat-Bullish

    J.P. Morgan Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $30

    J.P. Morgan has reiterated its Buy rating for Kura Oncology (KURA.US) and maintained its price target of $30. This suggests a continued positive outlook from the firm regarding the company's stock performance.

    Moomoo•10/14/26•Bullish

    Cantor Fitzgerald reiterates Kura Oncology stock rating at Overweight

    Cantor Fitzgerald has reiterated an Overweight rating on Kura Oncology (NASDAQ: KURA) following a webinar about its spin-out, Caspian Therapeutics...

    Investing.com•10/14/26•Bullish

    Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes - Slideshow (NASDAQ:KURA)

    Kura Oncology, Inc. (KURA) has released a slideshow discussing data and its development strategy for menin inhibitors, specifically KO-7246...

    Seeking Alpha•10/13/26•Neutral

    KURA Valuation and Fair Value

    P/E
    -2.9x
    P/FCF
    -7.3x
    PEG
    0.0x
    P/B
    17.8x
    See GNG's fair value

    KURA Profitability: Margins, ROIC and FCF

    Gross margin
    99.3%
    Operating margin
    -349.8%
    Net margin
    0.0%
    ROIC
    -546.3%
    ROE
    -167.7%
    FCF margin
    -152.1%
    FCF yield
    -13.6%

    KURA Competitors

    CompanyTicker
    Rigel Pharmaceuticals IncRIGL
    Si-Bone IncSIBN
    MoonLake ImmunotherapeuticsMLTX
    Jade Biosciences, Inc.JBIO
    Theravance Biopharma IncTBPH
    Alto Neuroscience, Inc.ANRO
    Beta Bionics, Inc. Common StockBBNX
    Cullinan Oncology LLCCGEM

    Sector: Healthcare

    KURA Analyst Ratings

    Consensus
    Buy
    Analysts
    15
    Strong Buy
    2
    Buy
    12
    Hold
    1
    Sell
    0
    Strong Sell
    0

    KURA Bull Case vs Bear Case

    Bull case

    • KURA grew quarterly revenue 36.5% year over year.
    • 93.3% of KURA's analyst ratings are Buy or Strong Buy.

    Bear case

    • KURA beat EPS estimates in 37.5% of its last 8 reported quarters.

    KURA Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -79.8%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.81
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    7 up, 0 down

    Frequently Asked Questions About KURA

    Does KURA pay dividends?

    Kura Oncology Inc (KURA) does not currently pay a regular dividend.

    What is KURA's market cap?

    Kura Oncology Inc (KURA) has a market capitalization of $874.48M with a current stock price of $9.70.

    Related stocks

    Sector: Healthcare

    All stocks starting with K

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In